ERBB2 and breast cancer: Triple-negative breast cancer (TNBC), which accounts for 10–15% of all breast cancers, lacks amplification of estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor-2 (HER2) [1].